
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

November 7, 2014

OPKO Health, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-33528

75-2402409

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

4400 Biscayne Blvd., Miami, Florida

33137

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(305) 575-4100

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure.

On November 7, 2014, OPKO Health, Inc., a Delaware corporation (the “Company”), issued a press release announcing that the Company will hold a conference call to provide a business update and discuss its third quarter 2014 financial results. A copy of the press release is attached hereto as Exhibit 99.1.

The information included herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release of the Company dated November 7, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.

November 10, 2014

By: /s/ Adam Logal

Name: Adam Logal

Title: Senior Vice President-Chief Financial Officer

Exhibit Index

Exhibit No.	Description
99.1	Press Release of the Company dated November 7, 2014



OPKO To Hold Conference Call on November 10, 2014

MIAMI – November 7, 2014 — OPKO Health, Inc. (NYSE:OPK) will hold a conference call to provide a business update and discuss its third quarter 2014 financial results on Monday, November 10, 2014, before the market opens. OPKO's senior management team will host a conference call and live audio webcast at 8:30 a.m. ET on Monday, November 10, 2014 to discuss the Company's results in greater detail.

The conference call will be available via phone and webcast. The conference call dial-in information is listed below. To access the webcast, please log on to the OPKO website at www.opko.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. A link to the live webcast is also included below.

CONFERENCE CALL & WEBCAST INFORMATION:

WHEN: Monday, November 10, 2014, 8:30 a.m. ET

DOMESTIC & CANADA DIAL-IN: 1-877-407-0789

INTERNATIONAL DIAL-IN: 1-201-689-8562

LIVE WEBCAST LINK: <http://investor.opko.com/events.cfm>

For those unable to participate in the conference call or webcast, a replay will be available beginning November 10, 2014 at 11:30 a.m. ET until December 10, 2014 at 11:59 p.m. ET. To access the replay, dial 1-877-870-5176 or international dial 1-858-384-5517. The replay passcode is 13595548.

The replay can also be accessed for 30 days on OPKO's website at www.opko.com.

About OPKO Health, Inc.

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.

OPKO Health, Inc.

Les Funtleyder (305) 575-6013